Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555482 | 1.00 | ERBB2 (0.53) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5385106 | 0.90 | ERBB2 (0.66) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5385109 | 0.90 | ERBB2 (0.66) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5557888 | 0.89 | ERBB2 (0.64) | ERBB2MINK1RXRAGRIN1GRIN2B | |
| SCHEMBL5557895 | 0.89 | ERBB2 (0.64) | ERBB2MINK1RXRAGRIN1GRIN2B | |
| SCHEMBL5562245 | 0.85 | ERBB2 (0.49) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5562249 | 0.85 | ERBB2 (0.49) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5562942 | 0.85 | ERBB2 (0.43) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5558261 | 0.82 | ERBB2 (0.48) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5558266 | 0.82 | ERBB2 (0.48) | ERBB2MINK1FGFR1FLT1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758897-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-07 | — | — | EP | claimed |
| US-7179812-B2 | Diazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-20 | — | — | US | claimed |
| WO-2005097785-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-20 | — | — | WO | claimed |
| US-20050222228-A1 | Novel diazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-10-06 | — | — | US | claimed |
| CN-1934106-A | Novel diazine derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | CN | disclosed |
| EP-1758897-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| US-7179812-B2 | Diazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2005097785-A1 | NOVEL DIAZINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222228-A1 | Novel diazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222228-A1 | Novel diazine derivatives | BRCA1, SLC5A1, PDHA1 | ERBB2 1298/4885MINK1 749/4885FGFR1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.